Ionis Pharmaceuticals (IONS) reported a Q1 net loss Wednesday of $0.93 per diluted share, narrowing from a loss of $0.98 a year earlier.
Analysts polled by FactSet expected a loss of $1.10.
Revenue for the quarter ended March 31 was $132 million, up from $119 million a year earlier.
Analysts surveyed by FactSet expected $131.4 million.
The California life sciences company said it has lifted its 2025 revenue outlook to between $725 million to $750 million, up from its previous guidance of over $600 million. Analysts polled by FactSet expect $643.0 million.
Shares of the company were up more than 3.5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.